Related Experiment Video

Updated: Aug 17, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Estramustine resistance

S Sangrajrang1, F Calvo, A Fellous

  • 1Laboratoire de Pharmacologie, Institut de Génétique Moléculaire, Hôpital Saint-Louis, Paris, France.

General Pharmacology
|August 26, 1999
PubMed

Insights

Estramustine (EM), an antimicrotubule drug, shows promise beyond prostate cancer. Drug resistance to EM involves complex cellular adaptations, distinct from multidrug resistance, affecting tubulin and tau expression.

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Estramustine (EM) is an antimicrotubule agent used for advanced prostate cancer.
  • Emerging data suggest antitumor effects in other malignancies, with ongoing clinical studies.
  • EM's mechanism involves microtubule depolymerization via tubulin and microtubule-associated protein (MAP) binding.

Purpose of the Study:

  • To review the current understanding of Estramustine's effects.
  • To summarize the development and characteristics of Estramustine drug resistance.
  • To highlight the potential of EM in broader oncological applications.

Main Methods:

  • Literature review of experimental and clinical data on Estramustine.
  • Analysis of studies investigating Estramustine's mechanism of action.
  • Examination of research on Estramustine resistance mechanisms in cell lines.

Main Results:

  • Estramustine exhibits radiosensitizing properties, increasing clinical interest.
  • EM has demonstrated induction of apoptotic cell death in glioma models.
  • Estramustine resistance is a distinct phenotype, not linked to the multidrug resistance (MDR) phenotype.
  • Resistance acquisition involves adaptive changes in tubulin expression and tau phosphorylation.

Conclusions:

  • Estramustine has potential applications beyond prostate cancer treatment.
  • Understanding Estramustine resistance is crucial for optimizing its clinical use.
  • The distinct resistance mechanisms suggest novel therapeutic strategies may be developed.

More Related Videos

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...